Diffusion Tensor Imaging in Boys With Adrenoleukodystrophy: Identification of Cerebral Disease and Association With Neurocognitive Outcomes.
Humans
Male
Adrenoleukodystrophy
/ diagnostic imaging
Diffusion Tensor Imaging
Child
Retrospective Studies
White Matter
/ diagnostic imaging
Corpus Callosum
/ diagnostic imaging
Adolescent
Pyramidal Tracts
/ diagnostic imaging
Child, Preschool
Hematopoietic Stem Cell Transplantation
Neuropsychological Tests
Cohort Studies
Brain
/ diagnostic imaging
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
ppublish
Résumé
Childhood cerebral adrenoleukodystrophy (C-ALD) is a severe inflammatory demyelinating disease that must be treated at an early stage to prevent permanent brain injury and neurocognitive decline. In standard clinical practice, C-ALD lesions are detected and characterized by a neuroradiologist reviewing anatomical MRI scans. We aimed to assess whether diffusion tensor imaging (DTI) is sensitive to the presence and severity of C-ALD lesions and to investigate associations with neurocognitive outcomes after hematopoietic cell therapy (HCT). In this retrospective cohort study, we analyzed high-resolution anatomical MRI, DTI, and neurocognitive assessments from boys with C-ALD undergoing HCT at the University of Minnesota between 2011 and 2021. Longitudinal DTI data were compared with an age-matched group of boys with ALD and no lesion (NL-ALD). DTI metrics were obtained for atlas-based regions of interest (ROIs) within 3 subdivisions of the corpus callosum (CC), corticospinal tract (CST), and total white matter (WM). Between-group baseline and slope differences in fractional anisotropy (FA) and axial (AD), radial (RD), and mean (MD) diffusivities were compared using analysis of covariance accounting for age, MRI severity (Loes score), and lesion location. Among patients with NL-ALD (n = 14), stable or increasing FA, stable AD, and stable or decreasing RD and MD were generally observed during the 1-year study period across all ROIs. In comparison, patients with mild posterior lesions (Loes 1-2; n = 13) demonstrated lower baseline FA in the CC splenium (C-ALD 0.50 ± 0.08 vs NL-ALD 0.58 ± 0.04; DTI was sensitive to lesion presence and severity as well as clinical neurocognitive effects of C-ALD. DTI metrics quantify C-ALD even at an early stage.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Childhood cerebral adrenoleukodystrophy (C-ALD) is a severe inflammatory demyelinating disease that must be treated at an early stage to prevent permanent brain injury and neurocognitive decline. In standard clinical practice, C-ALD lesions are detected and characterized by a neuroradiologist reviewing anatomical MRI scans. We aimed to assess whether diffusion tensor imaging (DTI) is sensitive to the presence and severity of C-ALD lesions and to investigate associations with neurocognitive outcomes after hematopoietic cell therapy (HCT).
METHODS
METHODS
In this retrospective cohort study, we analyzed high-resolution anatomical MRI, DTI, and neurocognitive assessments from boys with C-ALD undergoing HCT at the University of Minnesota between 2011 and 2021. Longitudinal DTI data were compared with an age-matched group of boys with ALD and no lesion (NL-ALD). DTI metrics were obtained for atlas-based regions of interest (ROIs) within 3 subdivisions of the corpus callosum (CC), corticospinal tract (CST), and total white matter (WM). Between-group baseline and slope differences in fractional anisotropy (FA) and axial (AD), radial (RD), and mean (MD) diffusivities were compared using analysis of covariance accounting for age, MRI severity (Loes score), and lesion location.
RESULTS
RESULTS
Among patients with NL-ALD (n = 14), stable or increasing FA, stable AD, and stable or decreasing RD and MD were generally observed during the 1-year study period across all ROIs. In comparison, patients with mild posterior lesions (Loes 1-2; n = 13) demonstrated lower baseline FA in the CC splenium (C-ALD 0.50 ± 0.08 vs NL-ALD 0.58 ± 0.04;
DISCUSSION
CONCLUSIONS
DTI was sensitive to lesion presence and severity as well as clinical neurocognitive effects of C-ALD. DTI metrics quantify C-ALD even at an early stage.
Identifiants
pubmed: 39151102
doi: 10.1212/WNL.0000000000209764
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e209764Références
Neurology. 2019 Dec 3;93(23):e2133-e2143
pubmed: 31719133
Neuroimage. 2018 Nov 15;182:207-218
pubmed: 29305910
Curr Neurol Neurosci Rep. 2014 Oct;14(10):486
pubmed: 25115486
Radiology. 2002 Oct;225(1):245-52
pubmed: 12355012
AJNR Am J Neuroradiol. 1994 Oct;15(9):1761-6
pubmed: 7847225
Blood. 2004 Aug 1;104(3):881-8
pubmed: 15073029
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Neuroimage. 2016 Jan 1;124(Pt A):473-486
pubmed: 26375208
Biol Blood Marrow Transplant. 2019 Mar;25(3):538-548
pubmed: 30292747
N Engl J Med. 2017 Oct 26;377(17):1630-1638
pubmed: 28976817
AJNR Am J Neuroradiol. 2013 Mar;34(3):641-9
pubmed: 22899791
Int J Neonatal Screen. 2022 Feb 18;8(1):
pubmed: 35225938
AJNR Am J Neuroradiol. 2008 May;29(5):843-52
pubmed: 18339719
J Inherit Metab Dis. 2023 Mar;46(2):174-193
pubmed: 36527290
Brain Imaging Behav. 2013 Dec;7(4):409-35
pubmed: 23329357
Int J Dev Neurosci. 2020 Feb;80(1):52-72
pubmed: 31909500
J Inherit Metab Dis. 2021 Nov;44(6):1434-1440
pubmed: 34499753
Dev Cogn Neurosci. 2018 Oct;33:161-175
pubmed: 29229299
Quant Imaging Med Surg. 2012 Dec;2(4):254-65
pubmed: 23289085
J Inherit Metab Dis. 2021 May;44(3):728-739
pubmed: 33373467
Med Image Anal. 2001 Jun;5(2):143-56
pubmed: 11516708
Blood. 2011 Aug 18;118(7):1971-8
pubmed: 21586746
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
Neurology. 2022 Aug 1;99(5):e512-e520
pubmed: 35609989
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Expert Opin Biol Ther. 2022 Sep;22(9):1151-1162
pubmed: 36107226
Glia. 2021 Oct;69(10):2362-2377
pubmed: 34137074
JAMA Netw Open. 2018 Jul 6;1(3):e180769
pubmed: 30646031
Pediatr Radiol. 2010 Dec;40(12):1918-30
pubmed: 20577731
Ann Clin Transl Neurol. 2018 Jan 22;5(3):252-261
pubmed: 29560371
Neurology. 2020 Aug 4;95(5):e591-e600
pubmed: 32616675
AJNR Am J Neuroradiol. 2011 Mar;32(3):481-9
pubmed: 21273354
AJNR Am J Neuroradiol. 2003 May;24(5):819-24
pubmed: 12748077
AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1102-6
pubmed: 17569968
Neurology. 2003 Aug 12;61(3):369-74
pubmed: 12913200
Neurology. 2022 Nov 22;99(21):940-951
pubmed: 36175155
Neurobiol Aging. 2019 Nov;83:63-72
pubmed: 31585368
NMR Biomed. 2019 Apr;32(4):e3778
pubmed: 28886240
Neuropediatrics. 2021 Aug;52(4):252-260
pubmed: 34192790
Neuroimage. 2007 Jul 1;36(3):630-44
pubmed: 17481925
Brain Pathol. 2010 Jul;20(4):817-30
pubmed: 20626743
JAMA Neurol. 2017 Jun 1;74(6):710-717
pubmed: 28418523
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neurology. 2001 Feb 27;56(4):544-7
pubmed: 11222805
Neuroimage. 2002 Nov;17(3):1429-36
pubmed: 12414282
Neuroimage. 2008 Jan 1;39(1):336-47
pubmed: 17931890